These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 28978825)

  • 1. [Pathogenesis and treatment of anemia in chronic kidney disease].
    Nangaku M
    Rinsho Ketsueki; 2017; 58(10):1860-1863. PubMed ID: 28978825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
    Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical application and future perspectives of HIF-PH inhibitors].
    Nangaku M
    Nihon Yakurigaku Zasshi; 2024; 159(3):157-159. PubMed ID: 38692879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron Metabolism in Chronic Kidney Disease Patients.
    Honda H; Hosaka N; Ganz T; Shibata T
    Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease.
    Kaplan JM; Sharma N; Dikdan S
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilizing HIF to Ameliorate Anemia.
    Voit RA; Sankaran VG
    Cell; 2020 Jan; 180(1):6. PubMed ID: 31951520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
    Packer M
    Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and future chemical therapies for treating anaemia in chronic kidney disease.
    Locatelli F; Del Vecchio L; Luise MC
    Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia in conventional hemodialysis: Finding the optimal treatment balance.
    Hasegawa T; Koiwa F; Akizawa T
    Semin Dial; 2018 Nov; 31(6):599-606. PubMed ID: 29909605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
    Del Vecchio L; Locatelli F
    Expert Rev Hematol; 2014 Aug; 7(4):495-506. PubMed ID: 25025373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
    BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
    Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
    Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
    BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Treatment Approaches for the Anemia of CKD.
    Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
    Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors.
    Locatelli F; Minutolo R; De Nicola L; Del Vecchio L
    Drugs; 2022 Nov; 82(16):1565-1589. PubMed ID: 36350500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.